Assenagon Asset Management S.A. Sells 2,882,776 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Assenagon Asset Management S.A. trimmed its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 83.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 591,679 shares of the biotechnology company’s stock after selling 2,882,776 shares during the quarter. Assenagon Asset Management S.A. owned about 0.25% of ADMA Biologics worth $10,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics in the third quarter worth about $30,000. Larson Financial Group LLC purchased a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $31,000. National Bank of Canada FI bought a new position in ADMA Biologics during the 3rd quarter valued at approximately $35,000. GAMMA Investing LLC raised its stake in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in ADMA Biologics in the second quarter worth $29,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by insiders.

ADMA Biologics Stock Down 3.7 %

ADMA stock opened at $16.02 on Friday. The stock has a market capitalization of $3.79 billion, a P/E ratio of 57.21 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1-year low of $4.86 and a 1-year high of $23.64. The business has a fifty day moving average price of $19.04 and a 200-day moving average price of $17.29.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the company earned $0.01 EPS. Equities analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.